Preoperative Beta-Blocker Usage: Is It Really Worthy of Being a Quality Indicator? William T. Brinkman, MD, Morley A. Herbert, PhD, Syma L. Prince, RN, BSN, Mitchell J. Magee, MD, Todd M. Dewey, MD, Robert L. Smith, MD, James R. Edgerton, MD, Stuart J. Head, BS, William H. Ryan, MD, Michael J. Mack, MD The Annals of Thoracic Surgery Volume 92, Issue 3, Pages 788-796 (September 2011) DOI: 10.1016/j.athoracsur.2011.03.088 Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Change in observed to expected ratio for operative mortality with increasing use of β- blockers in the unmatched and matched patient groups. The Annals of Thoracic Surgery 2011 92, 788-796DOI: (10.1016/j.athoracsur.2011.03.088) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Relative risk/benefit for predefined subgroups of matched patient group. (LV = left ventricular.) The Annals of Thoracic Surgery 2011 92, 788-796DOI: (10.1016/j.athoracsur.2011.03.088) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions